Navigation
banner

Cell & Gene Therapy

2017-09-192017-08-112017-07-14
Register 3 for the price of 2 with the coupon code rcdvb!


Cell & Gene Therapy
KEYNOTE SPEAKERS
Richard Gatti

Richard Gatti
Distinguished Professor in the Departments of Pathology & Laboratory Medicine and Human Genetics
David Geffen UCLA School of Medicine
Richard Gatti
Distinguished Professor in the Departments of Pathology & Laboratory Medicine and Human Genetics
David Geffen UCLA School of Medicine
 
About Speaker:

Richard Gatti is a molecular biologist and geneticist who joined the UCLA School of Medicine faculty in 1974 as full professor. After a pediatric residency at Children???s Memorial Hospital in Chicago (1962-65), and serving as Captain, U.S. Army in Eritrea, Ethiopia (1966-68), he did post-doctoral fellowships with Robert A. Good, MD, PhD, at the University of Minnesota (1968-72) in basic and clinical immunology, and George Klein, MD, at the Karolinska Institute in Stockholm, Sweden (1972-75) in tumor biology. He served as Director of Pediatric Hematology, Oncology and Immunology at Cedars-Sinai Medical Center (1974-1980). He joined the Department of Pathology & Laboratory Medicine at UCLA in 1981. He founded the Molecular Diagnostics Laboratory (1987) and is co-director. He is also a member of the Department of Human Genetics (2005- _. He is Scientific Director of the Ataxia-Telangiectasia Medical Research Foundation (1984- ) as well as the Neuromuscular Diseases Foundation (2006- ). He was a recipient of a USPHS Research Career Development Award (1972-75) and has been funded by NIH or the Department of Energy since 1967. He has co-authored over 330 scientific articles. He pioneered the field of hematopoietic stem cell transplantation and other treatments for primary immunodeficiencies. His current research focuses on the molecular genetics, diagnostics, radiobiology, and treatment of children with ataxia-telangiectasia, a progressive neurological disease of children.

Philip Gregory

Philip Gregory
Chief Scientific Officer
Bluebird Bio
Philip Gregory
Chief Scientific Officer
Bluebird Bio
 
About Speaker:

Philip D. Gregory, D. Phil., has served as Chief Scientific Officer of bluebird bio since June 2015. Prior to joining bluebird Philip was at Sangamo BioSciences, Inc., where he held multiple leadership positions, most recently serving as Chief Scientific Officer and Senior Vice President, Research. Philip has led pioneering research in gene therapy and genome editing and was named by Thompson Reuters as one of “The World’s Most Influential Scientific Minds 2014” and “Most Cited Researchers 2015”. He served as a member of the Scientific Advisory Board of the Keystone Symposia from 2009 to 2015, and the ASGCT Advisory Council from 2016. Before joining the biotechnology industry Philip was at the University of Munich, Germany, where he studied the role of chromatin structure in gene regulation. Philip earned a D. Phil. in biochemistry from the University of Oxford (Keble College) and holds a B.Sc. in microbiology from the University of Sheffield.

James Wilson

James Wilson
Professor, Internal Medicine and Pathology & Laboratory Medicine; Director, Gene Therapy Program
University of Pennsylvania
James Wilson
Professor, Internal Medicine and Pathology & Laboratory Medicine; Director, Gene Therapy Program
University of Pennsylvania
 
About Speaker:

James M. Wilson, MD, PhD, is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has led an effort to develop the field of gene therapy. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago. He then moved to Boston to do a residency in Internal Medicine at the Massachusetts General Hospital and continued his work in gene therapy at MIT. Dr. Wilson has been at the nexus of this emerging therapeutic area from its birth. He created the first and largest academic-based program in gene therapy after being recruited to Penn in 1993. He initially focused on the clinical translation of existing gene transfer technologies but soon redirected his efforts to the development of second and third generation gene transfer platforms; the first of which was licensed to a biotechnology company he founded that resulted in the first, and only, commercially approved gene therapy in the western hemisphere.
More recently, his laboratory discovered a family of viruses from primates that could be engineered to be very effective gene transfer vehicles. These so called "vectors" have become the technology platform of choice and have set the stage for the recent resurgence of the field of gene therapy. Dr. Wilson has also been active in facilitating the commercial development of these new gene therapy platforms through the establishment of several biotechnology companies. He is currently leading a national dialogue on the challenges of commercializing these potentially lifesaving treatments due to the disruptive nature they will have on traditional business models. Throughout his career, the focus of Dr. Wilson’s research has been rare inherited diseases, ranging from cystic fibrosis to dyslipidemias to a variety of metabolic disorders.
Dr. Wilson has published over 550 papers, reviews, commentaries and editorials in the peer-reviewed literature and is an inventor on over 117 patents. He was the second President of the American Society of Gene Therapy. Dr. Wilson was the 2014 recipient of the William Osler Patient Oriented Research Award of the University of Pennsylvania and received the 2015 Scientific Achievement Award from Pennsylvania Bio. Dr. Wilson was noted by the journal Nature Biotechnology to be the “second most productive bio-entrepreneur in life sciences.” Dr. Wilson is a Trustee at Albion College and founder of a 501(c)3 called Health Through Fitness in Orphan Diseases. He is also the Director of a bicycle team called Rare Disease Cycling, whose participants compete at a national level and help raise money for rare disease research.

DISTINGUISHED SPEAKERS
Rajni Agarwal

Rajni Agarwal
Associate Professor and Medical Director, Division of Pediatric Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics
Stanford University
Rajni Agarwal
Associate Professor and Medical Director, Division of Pediatric Stem Cell Transplantation and Regenerative Medicine, Department of Pediatrics
Stanford University
 
About Speaker:

I trained extensively in India as a pediatric Hematologist-Oncologist. Due to a strong interest in pursuing translational research in the field I chose to come to the USA. During my stay at Children's Hospital Medical Center (CHMC) in Cincinnati, Ohio I developed a strong interest in the field of stem cell biology and transplantation. My experience in this field also included extensive training and expertise obtained at the hospital for sick children, Toronto, Canada and National Institute of Health (NIH), USA. At the hospital for sick children I developed stem cell assays and invivo models of human hematopoiesis that were critical in understanding of stem cell biology and its clinical applications. At the NIH I spent two years with Drs. Nienhuis and Cynthia Dunbar and developed gene transfer assays in Hematopoietic cells. At the NIH, I also worked on developing the mammalian models for in vivo gene transfer in hematopoietic cells. During this time we also published our work on chronic myeloid leukemia addressing the role of interaction of stromal cells with hematopoietic cells in the bone marrow. This publication defined conditions to favor the growth of benign hematopoietic cells in patients with chronic myeloid leukemia.
At CHMC, Cincinnati, I established the stem cell biology laboratory to further investigate the field of Hematopoietic stem cells specifically involving the umbilical cord blood. I started the clinical Umbilical cord blood transplant program at CHMC. Through my research efforts we were able to develop a sterile system for collection and use of cord blood cells. This endeavor later contributed in establishing methods to collect and store cord blood for clinical use. In the laboratory we were able to set up the assays to identify and collect highly purified hematopoietic cells from the cord blood. The engraftment and expansion potential of the cord blood derived hematopoietic cells was studied in the immune deficient mice. Also these models were then used to develop assays for gene transfer in Fanconi Anemia.

Currently, at Stanford my focus is to develop clinical research protocols to reduce toxicity from high doses of chemotherapy and radiation therapy, cellular therapies to reduce graft vs host disease, Graft manipulation to reduce complications from graft vs. host disease in patients who receive mismatched donor stem cells and develop cellular therapies to treat viral infections post transplant.
Throughout my academic career, I have maintained my interest and commitment in providing not only excellent patient care but to provide clinical research data which can be utilized to improve patient care at the end.

Gregory Alberts

Gregory Alberts
Global Subject Matter Expert
Lonza
Gregory Alberts
Global Subject Matter Expert
Lonza
 
About Speaker:

Dr. Gregory Alberts is currently the Global Subject Matter Expert for Lonza, and has worked at Lonza (and previously Amaxa) since 2003. He was the first field scientist hired by Amaxa in North America, and he has considerable experience in Nucleofection, primary cells (including stem cells and iPSC generation), and is well versed in the use of CRISPR and other genome-editing technologies with Nucleofection. He received a Ph.D. from the George Washington University in 2003 in Molecular Biology, and an M.S. in Bacterial Genetics from the University of Illinois-Chicago in 1986.

On a practical note, Dr. Alberts worked at the American Red Cross Holland Laboratory for 14 years in basic vascular and cancer research, worked for three years at Oncor, Inc. in molecular cancer diagnostics, and spent four years working on bacterial genetics and DNA uptake in Streptococcus pneumoniae at University of Illinois at Chicago.

Andrew Collard

Andrew Collard
Engagement Manager
Back Bay Life Science Advisors
Andrew Collard
Engagement Manager
Back Bay Life Science Advisors
 
About Speaker:

Andy Collard is an Engagement Manager at Back Bay Life Science Advisors, a healthcare-focused strategy consulting firm based in Boston. At Back Bay, Andy has led several of the firm’s projects working with market leading gene therapy and gene editing companies, advising on indication prioritization, enabling technologies, and articulating companies’ value proposition for potential investors. In addition to these projects, Back Bay has worked on several buy-side diligence projects evaluating orphan disease companies and programs, including gene therapy assets. Andy received his MBA with a focus in healthcare from Yale School of Management. Prior to Back Bay, he worked at Myriant Technologies, engineering new bacteria and yeast strains to produce renewable bio-based chemicals.

Greg Dombal

Greg Dombal
Chief Operating Officer
Halloran Consulting Group
Greg Dombal
Chief Operating Officer
Halloran Consulting Group
 
About Speaker:

Greg joined Halloran Consulting Group in 2007.  He focuses on helping emerging companies navigate challenges in product development while establishing appropriate clinical, regulatory, and compliance structures. Greg represents clients to worldwide regulatory agencies and routinely functions as an on-demand Head of Regulatory, Clinical, or Development.

Greg pairs over 25 years’ experience in worldwide regulatory affairs, quality assurance and clinical development with a willingness to challenge conventional, conservative approaches and find the best solution for each company and their products.  Before joining Halloran, Greg was responsible for the regulatory, quality assurance, and clinical groups at ArQule. At its peak, the programs he was responsible for encompassed 17 clinical studies with annual budgets in excess of $25 million.

Over his career, Greg has successfully filed over 45 clinical trial applications (IND, IDE or equivalent), attended over 75 regulatory agency meetings, presented to multiple Advisory Committees and helped companies respond to Warning Letters, 522 Orders, and Clinical Hold notices.  He has obtained Orphan Drug designation and/or Fast Track designation for fifteen individual products, successfully negotiated multiple Special Protocol Agreements, and has extensive involvement with NDA/MAA submissions resulting in multiple product approvals.

Ian Gaudet

Ian Gaudet
Director of Process Development
Miltenyi Biotec
Ian Gaudet
Director of Process Development
Miltenyi Biotec
 
About Speaker:

Dr. Ian Gaudet studied Bioengineering at the University of California, San Diego, and received his doctorate in Biomedical Engineering jointly from Rutgers University and the University of Medicine and Dentistry of New Jersey, with work focused on novel biomaterials for regenerative medicine applications. Following his Ph.D., Dr. Gaudet worked for Progenitor Cell Therapy (PCT) where he was the Sr. Engineer and then Director of Innovation and Engineering, leading a scientific and engineering team in support of design, development, and implementation of clinical cell therapy manufacturing processes, as well as cell therapy commercialization strategy consulting. Dr. Gaudet led multiple projects from tech transfer, through development, and into clinical manufacturing, including multiple gene-modified hematopoietic stem cell and T cell therapies. He joined Miltenyi Biotec in 2016 and is currently the Director of Process Development at Miltenyi’s contract development and manufacturing facility in Sunnyvale, CA, where he focuses on development and translation of novel cell therapy processes into clinical manufacturing and beyond.

Marcie Glicksman

Marcie Glicksman
Chief Scientific Officer
ORIG3N
Marcie Glicksman
Chief Scientific Officer
ORIG3N
 
About Speaker:

Marcie Glicksman, Ph.D. is the Chief Scientific Officer at ORIG3N. ORIG3N combines genetics and regenerative medicine by leading the development of allogeneic, iPSC (induced pluripotent stem cell)-derived cell therapies by leveraging the world’s largest, uniformly consented, HLA-matched cell bank. ORIG3N also offers a broad range of affordable DNA tests that help people learn more about their genes, and the role they play in health and wellness. Dr. Glicksman received a bachelor’s degree from Brown University and a Ph.D. degree in Neuroscience from Washington University.  Dr. Glicksman has over 75 publications and 12 issued patents. Dr. Glicksman has been in the field of drug discovery for more than 20 years. She worked in the bio-pharma-ceutical industry for 13 years and then was on the faculty for ten years at Harvard Medical School and Brigham and Women’s Hospital and Co-Directed the Laboratory for Drug Discovery in Neurodegeneration (LDDN). In her career, she has led multiple advanced therapeutic programs including drug candidates that were tested in the clinic. She is on the science advisory board for the Alzheimer’s Drug Discovery Foundation (ADDF) and the California Institute for Regenerative Medicine (CIRM), and reviews grants for NIH, Department of Defense, the Michael J Fox Foundation, Alzheimer’s Association, and Rett Foundation.

Michelle Hoffmann

Michelle Hoffmann
Senior Vice President
Back Bay Life Science Advisors
Michelle Hoffmann
Senior Vice President
Back Bay Life Science Advisors
 
About Speaker:
Peadar Mac Gabhann

Peadar Mac Gabhann
Chief Executive Officer
Biostór Ireland
Peadar Mac Gabhann
Chief Executive Officer
Biostór Ireland
 
About Speaker:

Peadar Mac Gabhann is a graduate of the National University of Ireland, University College Dublin, M.Sc. in Industrial Microbiology. He carried out post graduate research at the Netherlands Cancer Institute (NKI) Amsterdam, Biogen at ETH Zurich and the Faculty of Medicine at Kyoto University Japan. He joined Schering Plough Corporation (Merck) and was a key member of staff in the start-up of the first world-wide Biopharma facility in Cork for the commercial production of Interferon in 1983. As Director and board member of Schering Plough Japan, he led the company’s research and Asian business development operations. Peadar has more than 30 years’ experience in the international pharmaceutical industry. In the past 10 years he co-founded and directed two Life Science start-ups and participated in several international EU projects: He has presented a position paper on “Biobanks - Key Resources for Advancement of Biotechnology & Human Health” to the expert group of the EU Parliament on the Future of Medicine. He is national expert representing Ireland on the working group to establish a new ISO TC276 standard in Biobanking & Bioprocessing. He currently consults with Jacobs Engineering on the design and construction of major Biopharma facilities for Bristol Myers Squibb, Novo Nordisk & Shire.He lectures part-time in Pharmaceutical Business at Griffith College Dublin as well as running a certified Tissue Establishment in Wexford, Biostór Ireland.

 

Joseph Melenhorst

Joseph Melenhorst
Director of Product Development & Correlative Sciences (PDCS), Center for Cellular Immunotherapies (CCI); Adjunct Associate Professor of Pathology and Laboratory Medicine
University of Pennsylvania
Joseph Melenhorst
Director of Product Development & Correlative Sciences (PDCS), Center for Cellular Immunotherapies (CCI); Adjunct Associate Professor of Pathology and Laboratory Medicine
University of Pennsylvania
 
About Speaker:

Dr. J. Joseph Melenhorst is the Director of Product Development & Correlative Sciences (PDCS) at the Center for Cellular Immunotherapies (CCI), and Adjunct Associate Professor of Pathology and Laboratory Medicine, University of Pennsylvania (UPenn). After he obtained is MSc degree at the University of Nijmegen, Netherlands, and PhD degree at the University of Leiden, Netherlands, he did his post-doctoral research at the National Institutes of Health in Bethesda, Maryland, studying the biology of bone marrow failure syndromes, leukemia and graft-versus host immunology, and adoptive cell therapy.

 

Dr. Melenhorst was recruited to the University of Pennsylvania in 2012. The focus of his laboratory is to understand and improve the efficacy and safety of cellular immunotherapy through biomarker, mechanistic, and product development studies. His laboratory has uncovered key biomarkers of a chimeric antigen receptor (CAR) T cell therapy-associated toxicity, cytokine release syndrome (CRS), and developed predictive monitoring tools for CRS in leukemia 1. He furthermore identified the critical parameters determining success in CAR T cell therapies in leukemia 2 (and manuscripts under revision).

 

Lastly, his efforts include the development of a universal, streamlined, cost-effective and potent manufacturing process for T cell engineering and some of his insight has already been translated into clinical practice.

Christopher-Paul Milne

Christopher-Paul Milne
Director of Research
Tufts Center for the Study of Drug Development
Christopher-Paul Milne
Director of Research
Tufts Center for the Study of Drug Development
 
About Speaker:

Dr. Christopher Milne joined the Center for the Study of Drug Development at Tufts University (Tufts CSDD) in 1998 as a Senior Research Fellow and has published over 100 book chapters, CSDD reports, white papers, and journal articles. His research interests include: academic-industry collaborations; global disease, demographic and market access factors; and, FDA incentive programs. He is currently Director of Research at Tufts CSDD, Research Associate Professor at Tufts University School of Medicine, Innogen Center Associate (University of Edinburgh), and editorial board member of Therapeutic Innovation & Regulatory Science and Pharma Focus Asia. Dr. Milne received a BA from Fordham University, an MPH from The Johns Hopkins University, and holds doctoral degrees in veterinary medicine and law, respectively from the UNPHU and UNH School of Law.

Cliff Mintz

Cliff Mintz
Chairman & Chief Executive Officer
Bioinsights
Cliff Mintz
Chairman & Chief Executive Officer
Bioinsights
 
About Speaker:

Clifford S. Mintz, PhD has an extensive background in biopharmaceutical drug development, strategic planning and commercialization of biosimilar drugs.

He is the founder of BioInsights a biopharmaceutical consulting and education/training firm

Cliff received a B.S. in microbiology/animal science from Cornell University, a Ph.D. in Bacteriology from the University of Wisconsin-Madison and performed his post-doctoral studies at Oregon Health Sciences University and the College of Physicians & Surgeons, Columbia University

Kevin Murray

Kevin Murray
Vice President, Global Sales
BioSpherix Medical
Kevin Murray
Vice President, Global Sales
BioSpherix Medical
 
About Speaker:

Sales Manager for BioSpherix, Ltd. BS BioChemistry, MBA Finance & Marketing, 20+ Years experience in the Pharmaceutical/Biotech/Medical Research Industry.

Shashi Murthy

Shashi Murthy
Professor of Chemical Engineering
Northeastern University
Shashi Murthy
Professor of Chemical Engineering
Northeastern University
 
About Speaker:

Shashi Murthy is a Professor of Chemical Engineering and the Founding Director of the Michael J. and Ann Sherman Center for Engineering Entrepreneurship Education at Northeastern University. The core expertise of his lab is in cell purification and processing for therapeutic use. Prof. Murthy has co-authored over 70 publications and is an inventor on 7 issued or pending patents. He previously co-founded Quad Technologies which has products for releasable magnetic bead separation of cells and T cell activation. Prof. Murthy is the recipient of the U.S. National Science Foundation’s Faculty Early Career Development (CAREER) Award and the Søren Buus Award for Outstanding Research in Engineering at Northeastern University. Prof. Murthy received his Ph.D. from MIT and B.S. from the Johns Hopkins University and is a Fellow of the American Institute of Medical and Biological Engineering (AIMBE).

Mahendra Rao

Mahendra Rao
Vice President for Regenerative Medicine
New York Stem Cell Foundation
Mahendra Rao
Vice President for Regenerative Medicine
New York Stem Cell Foundation
 
About Speaker:

Mahendra Rao  received his MD from Bombay University in India and his PhD in Developmental Neurobiology from the California Institute of Technology. Mahendra Rao is widely known for his research involving human embryonic stem cells (hESCs), iPSC, and other somatic stem cells. Dr. Rao   has an extensive  academic  background  with faculty positions at several  institutions including  the National Insttitutes of Health, Johns Hopkins University School of Medicine, The National Centre for Biological Sciences in Bangalore, India, and the University of Utah School of Medicine.  Dr. Rao has published more than 300 papers on stem cell research and is the co-founder of a neural stem cell company Q therapeutics  and its subsidiary Neuro Q.

Dr. Rao serves on several editorial boards, review panels scientific advisory boards and company boards. He continues to work with the ISCT, ISSCR  and FDA on consent  and other regulatory authorities. Dr Rao is currently the Vice president of Research in Regenerative Medicine at Neuro Q and provides consulting service to several companies focused on regenerative medicine. He currently  serves  on the Board of CESCA, XCell and Stempeutics  and as a consultant  for the New York Stem Cell foundation. He continues to maintain an active research program in neural development and in evaluating cell based screening and therapy to treat disorders of the nervous system.

 

Denis Rodgerson

Denis Rodgerson
Director of Science
GTCbio
Denis Rodgerson
Director of Science
GTCbio
 
About Speaker:

Denis Rodgerson was born and received his education to the undergraduate level in Ireland. He studied at the University of Colorado, School of Medicine, where he was awarded a master’s and doctorate degree. He subsequently was appointed to a faculty position at the University of Colorado as Director of Analytical Toxicology and Head of Pediatric Laboratories. In 1974, Rodgerson accepted a position in the Department of Pathology and Laboratory Medicine at the University of California Los Angeles as Professor and Head of Clinical Chemistry and Toxicology. He later became Vice Chairman of the department and retired from UCLA in 1999, remaining as Professor Emeritus. He is a fellow or member of many national and international professional organizations and has served on numerous committees at UCLA and the University of California system-wide. Rodgerson has published more than 170 articles in the medical and scientific literature and is the holder of several patents. He has been a consultant to many institutions and corporations, including NASA, National Bureau of Standards, Hewlett Packard, and Beckman Instruments.  Following retirement from UCLA he was a founder of StemCyte, Inc. Arcadia, California, an umbilical cord blood banking company, where he served as Chief Operating Officer and Senior Vice President until 2002. In 2002 Rodgerson founded and became the first President and Chief Executive Officer of NeoStem, Inc., a company based on the collection, processing and storage of stem cells derived from adult peripheral blood. In January 2006, NeoStem, Inc. was acquired by Phase III Medical, Inc., and Rodgerson continued as Director of Stem Cell Science until 2014. Rodgerson now serves as Director of Science for GTCbio.

 

Denis-Claude Roy

Denis-Claude Roy
Professor, Director Cellular Therapy Laboratory
University of Montreal
Denis-Claude Roy
Professor, Director Cellular Therapy Laboratory
University of Montreal
 
About Speaker:

Denis-Claude Roy, M.D., FRCPC, Hôpital Maisonneuve-Rosemont, Professor of Medicine, Université de Montréal, Director of Research – East of Montreal, and Scientific director, Center of Excellence for Cell Therapy, Montréal, Canada.

 

Denis Claude Roy received his M.D. degree in 1982 from the University of Montreal (UofM).  After completing an Internal Medicine residency and training in Hematology at the University of Montreal, Dr. Roy did a research fellowship at Harvard University, in the Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston.  In 1990, Dr. Roy joined the Division of Hematology and Bone Marrow Transplantation at the Maisonneuve-Rosemont Hospital, University of Montreal, as Director of the Cell Therapy Laboratory and Clinical Program. He is currently a Full Professor of Medicine at the UofM.  His research interests focus on the immunobiology of stem cell transplantation, and particularly at the treatment of cell grafts to foster immunotolerance and develop immune therapies against cancer. He has chaired 15 Phase I-II clinical trials at the national and international level. He has published more than 100 original articles and book chapters in prestigious journals such as Cell, Science, PLoS Medicine, Nature Medicine and Blood. Dr. Roy is Co-Director of the ThéCell FRSQ Network. He is also CEO of CellCAN Regenerative Medicine and Cell Therapy Network (Network of Centres of Excellence), and CSO of the Centre for Commercialization of Cancer Immunotherapy (C3i). He is currently Director of Research for East-of-Montreal-CIUSSS, and Scientific Director of the Center of Excellence in Cellular Therapy (CETC), Hopital Maisonneuve-Rosemont.

 

Khalid Shah (updated)

Khalid Shah
Vice Chair of Research, Director Center for Stem Cell Therapeutics and Imaging
Harvard Medical School
Khalid Shah
Vice Chair of Research, Director Center for Stem Cell Therapeutics and Imaging
Harvard Medical School
 
About Speaker:

Dr. Shah is an Associate Professor at Harvard Medical School and the Director of the Center for Stem Cell Therapeutics and Imaging at BWH. He is also the Vice Chair of Research for the Department of Neurosurgery at BWH and a Principal Faculty at Harvard Stem Cell Institute in Boston. In recent years, Dr. Shah and his team have pioneered major developments in the stem cell therapy field, successfully developing experimental models to understand basic cancer biology and therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, Nature Reviews Cancer, JNCI, Stem Cells and Lancet Oncology. Recently, Dr. Shah's work has caught the attention in the public domain and as such it has been highlighted in the media world-wide including features on BBC and CNN. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. In an effort to translate the exciting therapies develped in his laboratory into clinics, he has recently founded biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.

Devyn Smith

Devyn Smith
Chief Operating Officer
Sigilon
Devyn Smith
Chief Operating Officer
Sigilon
 
About Speaker:

Devyn recently joined Sigilon, a biotechnology company, as its Chief Operating Officer tasked with building out strategy and operational elements of the company as it builds a portfolio of potential new medicines.  Prior to Sigilon, Devyn was part of Pfizer's Medicinal Sciences Division of R&D as Head of Business Operations & Strategy focused on both day to day business operations of the division, as well insuring implementable strategies are developed.  Medicinal Sciences encompasses the groups focused on discovery, formulation, and early manufacturing of the large molecule, small molecule, cell and gene therapy programs in Pfizer R&D.  Prior to this Devyn was Head of Strategy for the Pharmatherapeutics Division of Pfizer R&D focused on developing and implementing core strategies in Winning by Design in Small Molecules as well as optimizing the ROI on novel technology inventions.  Before this role, Devyn was part of Pfizer's Neusentis Research Unit in the UK as Chief Operating Officer responsible for strategy, operations and implementing key strategies.  In addition, he supported the Pharmatherapeutics Global Clinical Research Organization as the Chief Operating Officer.  He joined Pfizer's Strategic Management Group in August 2009.

Prior to joining Pfizer, Devyn was a principal for The Frankel Group (a boutique management consulting firm in New York City and Cambridge).  In his consulting experience, Devyn led a wide range of projects, across multiple therapeutic areas and a host of technology platforms, including basic R&D tools, regenerative medicine, gene therapy, and macromolecules/biologic products. Client relationships have ranged from large pharma to small biotech companies. Regenerative Medicine has been an area of strong focus with over 30 engagements, several published papers, and numerous invited conference presentations. Prior to joining The Frankel Group, Devyn worked as a management consultant at Adventis Corporation focused on clients in information intensive companies. 

Devyn received his Ph.D. in Genetics from Harvard Medical School where his research culminated in 12 publications in leading journals such as Cell, Nature, and Development.  He also holds an MS in Biology from Idaho State University and a BS in Zoology from Brigham Young University.

Sam Wadsworth

Sam Wadsworth
Chief Scientific Officer
Dimension Therapeutics
Sam Wadsworth
Chief Scientific Officer
Dimension Therapeutics
 
About Speaker:

Dr. Wadsworth is the Chief Scientific Officer of Dimension Therapeutics, Inc., a leader in discovering and developing new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology.  Dr. Wadsworth brings extensive drug discovery and development experience in the gene therapy and rare disease area. In his more than 20 years of industry experience at Genzyme and later Sanofi, he oversaw the discovery and translational research on multiple rare disease and gene therapy programs. Most recently before joining Dimension, he served as the head of gene therapy research and early development at Sanofi Genzyme. Previously, he served as group vice president for translational research at Genzyme. Dr. Wadsworth holds a Ph.D. from the University of Chicago and a B.A. from Southern Illinois University.